NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Eloxx Pharmaceuticals, Inc. ELOX
19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-6.0M
Growth
—
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -6.0
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2024 · Operating -38.8% · Net -49.4%
ROE
FY2022 · ROE -615.2%
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | −0.0 | −0.0 | 0.0 | 0.0 | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | −0.0 | −0.0 | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EPS, diluted $ | −0.49 | −0.84 | −6.63 | −16.65 | −38.15 | −0.86 | −1.34 | −1.45 | −4.75 | −2.60 | 1.67 | −1.31 | −2.53 | −5.11 | −7.81 | −0.14 | −0.67 | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | −0 | −0 | −0 | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | −615.2 | −409.2 | −148.9 | −128.6 | −146.8 | −193.1 | −1571.7 | −99.6 | −91.0 | −59.0 | −169.2 | −127.1 | −116.3 | −196.1 | −73.9 | −46.8 |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 | 0.03 | 0.00 | 0.02 | 0.02 | 0.01 | 0.00 | 0.09 | 0.08 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures · 2 divergences in 68 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 8 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures2 divergent
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007